Modalità suggerimenti è attiva Disattiva
Per spostarsi rapidamente tra i blocchi

Società: NewAmsterdam Pharma
LEI 984500B6549TF6E14D36

Nome dell'organizzazione
NewAmsterdam Pharma Co NV
Nome del paese
Paesi Bassi
Paese di registrazione
Paesi Bassi
Settore industriale
Preparazione farmaceutica e biotecnologia
Debito obbligazionario
-

Utilizza il più completo database finanziario

800 000

obbligazioni

Oltre 400

fonti di prezzo

80 000

azioni

9 000

ETF

Monitora il tuo portafoglio nel modo più efficiente
bond screener
Watchlist
Excel ADD-IN
Ottieni l'accesso

Ultimi dati di

Quotazioni

Richiesta inviata
Accesso negato
Inviare una domanda
Le quotazioni ricevute dai fornitori di informazioni sono indicative

Profilo

NewAmsterdam Pharma operates as a pharmaceutical company. The Company focuses on the research and development of transformative therapies for cardio-metabolic diseases. NewAmsterdam Pharma serves customers in the Netherlands.

Riconoscimenti

Notizie

28/03/2024 NewAmsterdam Pharma: , Including Exhibit 99.1, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended (the Securities Act ). The Information Contained In This Item 7.01, Including Exhibit 99.1, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
04/03/2024 NewAmsterdam Pharma: , Including Exhibit 99.1, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended (the Securities Act ). The Information Contained In This Item 7.01, Including Exhibit 99.1, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
28/02/2024 NewAmsterdam Pharma: Of This Current Report On Form, Financial Statements And Exhibits
13/02/2024 NewAmsterdam Pharma: The Information Contained In This Item 7.01, Including Exhibits 99.1 And 99.2, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act. The Information Contained In This Item 7.01, Including Exhibits 99.1 And 99.2, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
22/01/2024 NewAmsterdam Pharma: Regulation Fd Disclosure, Financial Statements And Exhibits
Notizie societari

Documentazione

Rendicontazione IFRS/US GAAP

2023
IV trim. ingl.
2022
IV trim. ingl.
Mostra tutto Nascondi
Occorre effettuare il login
i dati è necessario l'accesso

Azioni

Debito obbligazionario in valuta

Mostra di più Nascondi

Codici

  • LEI
    984500B6549TF6E14D36
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001936258

Credito e ESG Rating

Indicatori Macroeconomici

La registrazione è richiesta per ottenere l'accesso.